Literature DB >> 21532224

A case of drug-induced hepatic injury associated with sitagliptin.

Megumi Toyoda-Akui1, Hiroaki Yokomori, Fumihiko Kaneko, Yuki Shimizu, Hajime Takeuchi, Kumiko Tahara, Tadashi Motoori, Makoto Ohbu, Masaya Oda, Toshifumi Hibi.   

Abstract

A 58-year-old man with a 10-year history of type II diabetes mellitus presented with progressive jaundice that began three days before admission. Thorough history-taking revealed that the patient had started on a new medication, sitagliptin, one month previously for the treatment of diabetes mellitus. Laboratory investigations showed severe liver dysfunction. Ultrasonography detected no extrahepatic biliary duct dilatation or gallstones. Abdominal computed tomography excluded pancreatic and hepatic focal lesions. Liver function improved upon discontinuation of sitagliptin. Drugs are an important, often unrecognized, cause of acute liver injury. This report presents a rare case in which sitagliptin was responsible for acute hepatic damage. As demonstrated, a thorough drug history is helpful in any case of unexplained liver injury.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21532224     DOI: 10.2169/internalmedicine.50.5057

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

1.  The incretin enhancer, sitagliptin, exacerbates expression of hepatic inflammatory markers in rats fed a high-cholesterol diet.

Authors:  Rashmi Pathak; Avinash Kumar; Henry A Palfrey; Laura A Forney; Kirsten P Stone; Narayan R Raju; Thomas W Gettys; Subramanyam N Murthy
Journal:  Inflamm Res       Date:  2019-05-09       Impact factor: 4.575

2.  Acute Liver Injury Induced by Sitagliptin: Report of Two Cases and Review of Literature.

Authors:  Amir Shahbaz; Kashif Aziz; Muhammad Umair; Mohaddeseh Sharifzadeh; Issac Sachmechi
Journal:  Cureus       Date:  2018-06-11

3.  Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague-Dawley rats fed a high-cholesterol diet.

Authors:  Rashmi Pathak; Avinash Kumar; Henry A Palfrey; Kirsten P Stone; Narayan R Raju; Thomas W Gettys; Subramanyam N Murthy
Journal:  Inflamm Res       Date:  2022-05-16       Impact factor: 4.575

4.  Antidiabetic Drug Sitagliptin with Divalent Transition Metals Manganese and Cobalt: Synthesis, Structure, Characterization Antibacterial and Antioxidative Effects in Liver Tissues.

Authors:  Samy M El-Megharbel; Najah M Al-Baqami; Eman H Al-Thubaiti; Safa H Qahl; Bander Albogami; Reham Z Hamza
Journal:  Curr Issues Mol Biol       Date:  2022-04-20       Impact factor: 2.976

Review 5.  Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Clin Pharmacokinet       Date:  2014-09       Impact factor: 6.447

6.  Liraglutide-induced autoimmune hepatitis.

Authors:  Emily Kern; Lisa B VanWagner; Guang-Yu Yang; Mary E Rinella
Journal:  JAMA Intern Med       Date:  2014-06       Impact factor: 21.873

7.  High levels of dietary methionine improves sitagliptin-induced hepatotoxicity by attenuating oxidative stress in hypercholesterolemic rats.

Authors:  Avinash Kumar; Rashmi Pathak; Henry A Palfrey; Kirsten P Stone; Thomas W Gettys; Subramanyam N Murthy
Journal:  Nutr Metab (Lond)       Date:  2020-01-06       Impact factor: 4.169

8.  Kombiglyze (metformin and saxagliptin)-induced hepatotoxicity in a patient with non-alcoholic fatty liver disease.

Authors:  Abdul Malik Thalha; Sanjiv Mahadeva; Alexander Tong Boon Tan; Kein Seong Mun
Journal:  JGH Open       Date:  2018-10-01

9.  Sitagliptin-Dependent Differences in the Intensity of Oxidative Stress in Rat Livers Subjected to Ischemia and Reperfusion.

Authors:  Małgorzata Trocha; Małgorzata Krzystek-Korpacka; Anna Merwid-Ląd; Beata Nowak; Małgorzata Pieśniewska; Piotr Dzięgiel; Agnieszka Gomułkiewicz; Przemysław Kowalski; Dorota Diakowska; Adam Szeląg; Tomasz Sozański
Journal:  Oxid Med Cell Longev       Date:  2019-10-31       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.